You're listening to Plenary Session.

This week on Plenary Session, you're in for a real treat. First, I'm still sick.

Perhaps I'm sick with something different, but perhaps it's the same thing lingering. It's hard to know.

But I will someday recover, and then you'll be in for the real full-forced plenary session.

But right now, you get a half dose.

So this week on plenary session, we have two things we're going to talk about.

We're going to talk about association of patient characteristics and tumor genomics

with clinical outcomes among patients with non-small cell lung cancer using a clinical genomic database.

This is by Garof Singh All and colleagues and appeared in Jama.

Next, we're going to talk about the long-awaited Sabre Comet, the randomized phase 2 trial that should not lead anyone to change their standard of care

right now and should lead to a randomized phase three study. That saber comet is finally out in

the Lancet and we get to put those headlines that appeared just a few months ago to the test. You

won't want to miss this. Stay tuned. But first, a plug. If you like this podcast, do us a favor

and recommend it to a friend. Plenary session wants to grow its audience and the best way to do so

is to get a personal recommendation from someone you know or trust. So recommend it to someone

and have them check out an episode.

Also, consider supporting us on Patreon.

Patreon.com allows you to support artists or podcasts that you appreciate,

and if you like this podcast, that's a great way to show your support.

Finally, if you haven't yet gone on to the iTunes store and written us a review,

we greatly appreciate it. Tell us what you think about this podcast and written us a review, we greatly appreciate it.

Tell us what you think about this podcast and give us five stars if we've earned it.

...